Clinical Trials Browser

Phase 2 × Withdrawn × Interventional × Clear all

NCT06708702 2026-04-09

Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy

Phase 2 Withdrawn

Stomatitis, Ulcer

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07030699 2026-04-07

ECLAT

Phase 2 Withdrawn

Lymphoma

NCT06152523 2026-04-06

MONAMI

Phase 2 Withdrawn

Neoplasms

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2 Withdrawn

CRC

NCT02143804 2026-04-02

exBOND

Phase 2 Withdrawn

Adenoviridae Infections, Urinary Bladder Neoplasms

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT06713798 2026-03-23

INDIGO

Phase 2 Withdrawn

Lung Neoplasms

NCT06654050 2026-03-17

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06710197 2026-03-05

OZM-034

Phase 2 Withdrawn

Early Stage Triple Negative ER Low Breast Cancer

NCT07223567 2026-02-25

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT06297629 2026-02-24

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06868238 2026-02-18

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Phase 2 Withdrawn

Carcinoma, Intraductal, Noninfiltrating, Lymphedema

NCT05487859 2026-02-17

Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Phase 2 Withdrawn

Kidney Neoplasms

NCT06501989 2026-02-11

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04482933 2026-02-10

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Phase 2 Withdrawn

Brain Neoplasms, Glioblastoma, Glioma, Herpes Simplex, Neoplasms, Virus Diseases

NCT07323576 2026-02-09

INAVO-CRC

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04285268 2026-01-30

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06068881 2026-01-30

Mandolin

Phase 2 Withdrawn

Lymphoma, Follicular

NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

Phase 2 Withdrawn

Meningioma

NCT05846724 2026-01-22

PULSAR

Phase 2 Withdrawn

Sarcoma, Kaposi

NCT06967987 2026-01-21

BEMAFLOT

Phase 2 Withdrawn

Adenocarcinoma

NCT06646016 2025-12-26

EPIC

Phase 2 Withdrawn

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT06116578 2025-12-01

NeoSarc

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT07026916 2025-11-17

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT06060587 2025-10-22

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Phase 2 Withdrawn

Prostatic Neoplasms

NCT04910425 2025-10-21

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06557278 2025-10-21

COMUNITY

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT05483023 2025-10-14

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Phase 2 Withdrawn

Endometrial Neoplasms

NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05046782 2025-09-30

Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06527690 2025-09-29

REPRESENTATION

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT04784221 2025-09-17

NANOPRO

Phase 2 Withdrawn

Recurrence

NCT06670105 2025-09-17

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Phase 2 Withdrawn

Lymphoma, B-Cell

NCT05472623 2025-09-15

Neo-Kan

Phase 2 Withdrawn

Resectable Non-Small Cell Lung Cancer

NCT06410534 2025-09-11

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2 Withdrawn

Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT00210171 2025-09-10

BIB 01

Phase 2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06084689 2025-09-02

EMPIRE

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06555263 2025-08-22

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms